New Jersey's cannabis regulatory landscape continues to evolve through both state legislation and federal developments. Since the CREAMM Act established the foundational framework in 2021, legislators have introduced and passed bills addressing hemp regulation, satellite dispensaries, home cultivation, medical access, and recriminalization debates. This page tracks the most significant recent and pending legislation.

Recently Enacted Legislation

S4509 — Hemp Regulation (January 2026)

Signed into law in January 2026, S4509 addresses the growing regulatory gap between legal cannabis and the largely unregulated hemp-derived THC market. Key provisions include:

• Establishing regulatory oversight of hemp-derived cannabinoid products (including Delta-8 THC)
• Aligning hemp product testing and labeling requirements with those for licensed cannabis products
• Closing loopholes that allowed intoxicating hemp products to be sold without age verification or testing

This legislation was a priority for the licensed cannabis industry, which argued that unregulated hemp-derived products created an uneven competitive landscape and posed consumer safety risks.

Satellite Dispensaries (Effective April 20, 2026)

Beginning April 20, 2026, Class 5 Retailer licensees will be permitted to open up to 3 satellite dispensary locations each. This expansion is expected to:

• Significantly increase the total number of dispensary locations across the state
• Improve access in underserved areas where no dispensary currently operates
• Allow established operators to expand their retail footprint without obtaining new licenses

The April 20 effective date (4/20) was a deliberate choice by lawmakers. Critics have raised concerns that satellite dispensaries will primarily benefit large operators who have the capital to open multiple locations, potentially widening the gap between MSOs and smaller licensees.

Pending and Active Bills

S3171 — Recriminalization Concerns

S3171 has generated significant controversy in the cannabis community. The bill has been characterized by opponents as a potential step toward recriminalization of certain cannabis-related activities. Details of the bill have prompted pushback from:

• Cannabis industry operators concerned about market stability
• Social justice advocates who view any criminalization as regressive
• The CRC, which has advocated for a regulatory rather than criminal approach

The bill's status and ultimate outcome remain closely watched by the industry.

S2564 — Home Grow

S2564 would authorize home cultivation of cannabis for personal use by adults 21 and older. New Jersey is currently one of the few states that legalized recreational cannabis without permitting home grow. Key provisions under consideration include:

• Allowing a limited number of plants per household for personal use
• Setting security and storage requirements for home cultivation
• Prohibiting sale or distribution of home-grown cannabis

The home grow debate pits consumer advocates (who argue that growing cannabis should be a fundamental right of legalization) against the licensed industry (which argues that home grow undercuts the regulated market and its tax revenue).

A1674 / S1758 — Medical Home Grow

A companion to the broader home grow discussion, A1674/S1758 specifically addresses home cultivation for medical cannabis patients. The argument for medical home grow is particularly strong:

• Medical patients may require consistent access to specific strains or preparations not always available at dispensaries
• Cost savings for patients who face significant out-of-pocket expenses for medical cannabis
• Self-sufficiency for patients in areas without convenient dispensary access

Medical home grow has somewhat broader bipartisan support than recreational home grow.

S1792 / A898 — Medicaid Cannabis Subsidy

This bill proposes that New Jersey's Medicaid program cover or subsidize medical cannabis for qualifying low-income patients. If enacted, it would:

• Address the affordability barrier for low-income medical cannabis patients
• Make New Jersey one of the first states to integrate medical cannabis into a public health insurance framework
• Potentially increase the medical patient population significantly

The bill faces challenges related to federal Medicaid rules (since cannabis remains federally illegal), cost estimates, and questions about implementation mechanics.

Federal Developments

Trump Rescheduling Order (December 2025)

In December 2025, President Trump issued an executive order directing federal agencies to proceed with the rescheduling of cannabis from Schedule I to Schedule III of the Controlled Substances Act. If implemented, rescheduling would have significant implications for New Jersey's cannabis industry:

• Section 280E relief: Moving to Schedule III would eliminate the 280E tax provision that prevents cannabis businesses from deducting standard business expenses on federal returns — a massive financial impact
• Banking access: Rescheduling could ease banking restrictions, making it easier for NJ cannabis businesses to access financial services
• Research: Schedule III status would facilitate cannabis research by removing many of the regulatory barriers that have limited scientific study
• State programs remain: Rescheduling does not legalize recreational cannabis federally — state programs like NJ's would continue operating under state authority

The rescheduling process is ongoing and faces legal and administrative challenges. The timeline for completion remains uncertain.

What These Bills Mean for NJ Cannabis

The current legislative agenda reflects several themes:

• Market maturation: Satellite dispensaries and hemp regulation show a market moving from startup phase to competitive maturity
• Consumer rights: Home grow bills reflect growing consumer demand for cultivation rights that most legal states already permit
• Access and affordability: Medicaid coverage proposals address the cost burden on medical patients
• Regulatory refinement: Hemp regulation closes gaps that emerged as the legal market developed
• Political tensions: The recriminalization debate shows that cannabis policy remains contested terrain even in a state that legalized by 67% voter approval

Staying Informed

To track NJ cannabis legislation:

• Subscribe to CRC GovDelivery alerts for regulatory updates
• Follow the NJ Legislature's bill tracking system at njleg.state.nj.us
• Monitor NJ CannaBusiness Association updates for industry advocacy perspectives
• Attend CRC public meetings for direct insight into regulatory decisions